Hypertrophic Cardiomyopathy Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
The Hypertrophic Cardiomyopathy Therapeutics Market is expected to grow at a CAGR of 1.8% over the forecast period (2022-2027).
Covid-19 has a considerable effect on all major organ systems. Due to the rising number of cases of Covid-19 in the initial stages of the pandemic, all hospitals around the world canceled medical visits and the target population remained indoors fearing the infection. However, the underlying cardiac disease, including heart failure (HF), is associated with increased SARS-CoV-2-related mortality. Thus, the risk of hypertrophic cardiomyopathy (HCM) increased during the pandemic. The research and developments increased for the development of advanced therapeutics for the treatment of HCM patients infected with Covid-19. An international multicenter study was conducted, and the results were published in the article “Impact of SARS-Cov-2 Infection in Patients with Hypertrophic Cardiomyopathy: Results of an International Multicentre Registry” in June 2022. As per the study results, 1/4th of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Additionally, age and cardiac features related to HCM showed an increased risk of mortality. Thus, this generated demand for the development of drugs of therapies for patient survival during the pandemic. Therefore, the pandemic is predicted to significantly impact the market studied.
Factors such as the rise in obesity and sedentary lifestyle population coupled with new product development for targeted cardiac disorders are expected to positively impact the market growth.
The market is driven primarily by the global burden of obesity and the sedentary lifestyle of the population. For instance, the data updated by World Health Organization (WHO) in June 2021 shows that obesity has increased globally, and it has tripled in the past two decades. In addition, the World Population Review’s survey “Obesity Rates by Country 2022” results show that about 13% of adults are obese and about 39% of adults are overweight globally. As per the article “Clinical Significance of Overweight in Patients with Hypertrophic Cardiomyopathy” published in October 2021, overweight patients were associated with more heart failure (HF) rehospitalization in HCM patients and being overweight was an independent determinant of major adverse cardiovascular and cerebral events (MACCE) in HCM patients. Thus, the burden of obesity and overweight coupled with the risk of heart failure among hypertrophic cardiomyopathy (HCM) patients with obesity demands the availability of therapeutics for treatment. Thereby driving the market growth.
Additionally, the data updated for “Hypertrophic Cardiomyopathy” by the “National Library of Medicine” in June 2022, the prevalence of HCM in the general population around the world is 0.2%, as determined from echocardiographic studies. Additionally, as per the source mentioned above, morphologic evidence is found in approximately 25% of first-degree relatives of patients with HCM. Thus, the high burden of the disease is demanding therapeutics for the treatment and patient survival. Therefore, it is expected to propel the studied market growth over the forecast period.
Therefore, owing to the above-mentioned factors the market studied is expected to grow over the forecast period. However, the technological advancement in devices is one of the major factors that is anticipated to hinder the market growth.
Key Market TrendsBeta-Adrenergic Blocking Agents Segment is Expected to Witness Growth Over the Forecast PeriodBeta-blockers function by obstructing the actions of the hormone epinephrine and referred to as adrenaline. Beta-blockers reduce blood pressure by causing the heart to beat more gradually and gently. Beta-adrenergic blockers (β-blockers) are an important class of drugs that are primarily prescribed by cardiologists for the treatment of various heart diseases including thickened heart muscle (hypertrophic cardiomyopathy (HCM)), among others. Thus, owing to the efficacy of the beta-blockers for the treatment of HCM is predicted to fuel the segment growth over the analysis period.
Various research shows that beta-adrenergic blockers prevent catecholamines from binding to the receptor sites which results in a decrease in heart rate, heart contraction, and blood pressure. This shows the effects of beta-adrenergic blockers on the heart, lungs, and blood vessels. In addition, the article “Beta-Blockers and Exercise Hemodynamics in Hypertrophic Cardiomyopathy” published in April 2022 stated that, despite a lack of trial evidence, beta-blockers have long been regarded as a first-line treatment for HCM. Therefore, the adoption of Beta-Adrenergic Blocking Agents or beta-blockers for the treatment of HCM is expected to boost segment growth.
Moreover, the recent developments and clinical trials in the segment are increasing recently. For instance, in August 2022, a clinical trial was registered titled “A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM) (DISCOVER-HCM)” with the objective to evaluate the safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) treated in the real-world setting. The patients of the trial will be given beta-blocker (BB)/non-dihydropyridine(non-DHP) calcium channel blocker (CCB)/disopyramide as prescribed by a physician. Such advancements in the segment are expected to fuel segment growth.
Therefore, owing to the factors mentioned above, the segment is anticipated to witness growth over the forecast period.
North America is Expected to Dominate the Market and Expected to do Same in the Forecast PeriodNorth America is anticipated to witness growth over the forecast period and dominate the market. Among other countries in the region, the United States is leading the market, due to factors such as an increase in healthcare expenditure, increasing research and developments, and a rising prevalence of various communicable or non-communicable diseases. Additionally, the rising geriatric population across the United States is the primary driver for the United States syndromic multiplex diagnostic market.
For instance, as per the data submitted in the article “Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era” published in January 2022, hypertrophic cardiomyopathy is the most prevalent type of inherited hereditary heart disease and, the prevalence of HCM in the United States is estimated to be 1 in 500 persons, yet a sizable portion of patients go undiagnosed. Thus, such a high burden of the disease is demanding therapeutics for the treatment and patient survival. Therefore, it is expected to propel the studied market growth in the region over the forecast period.
Moreover, the development activities by the market players in the form of product launches, acquisitions, mergers, and investments are also expected to enhance the market growth. For example, in October 2021, MyoKardia, Inc. registered a Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM).
In addition, in February 2022, Cytokinetics, Incorporated opened enrollment for SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten is a next-generation cardiac myosin inhibitor in development for the potential treatment of HCM. SEQUOIA-HCM builds on the positive results from REDWOOD-HCM, a Phase 2 clinical trial of aficamten, that demonstrated that treatment with aficamten for 10 weeks resulted in reductions from baseline compared to placebo in the average resting left ventricular outflow tract pressure gradient (LVOT-G) and the average post-Valsalva LVOT-G, with no treatment interruptions or discontinuations, nor any treatment-related serious adverse events. Thus, these increasing developments in the market across all the countries in North America are anticipated to drive market growth over the forecast period in the country.
Therefore, owing to the factors mentioned above, North America is predicted to be the major market for syndromic multiplex diagnostics, which is expected to witness growth over the forecast period.
Competitive LandscapeThe Hypertrophic Cardiomyopathy Therapeutics Market is moderately consolidated competitive and consists of of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently domianting the market are Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANZ PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., Bayer AG.
Additional Benefits:Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook